These emerging therapies , Semaglutide , represent a significant advancement in managing type 2 diabetes and potentially associated ailments . They are classified as GLP-1 receptor stimulators, indicating they to emulate the body's GLP-1 peptide, enhancing metabolic production and suppressing app